Post-infectious Basal Ganglia Encephalitis Caused by Mumps: A Case Series.

J Child NeurolMar 10, 2026 (epub)

Mahesh Kamate, Gayatri Pawar, Virupaxi Hattiholi

✦ AI-curated · Sources linked

Case in brief

The report describes five patients with basal ganglia encephalitis associated with mumps infection. They had a recent history of parotitis or febrile illness and serologic evidence of mumps, followed by acute movement disorders and behavioral changes, sometimes with seizures. Neuroimaging showed basal ganglia abnormalities. Extrapyramidal symptoms emerging as patients recovered from a febrile illness and clinical improvement after immunomodulatory therapy supported the diagnosis. Recovery was slower and hospitalization longer than for other mumps complications; the abstract does not provide individual outcomes or treatment details.

What made this case unusual

The neurologic syndrome could emerge during recovery from a febrile illness, with extrapyramidal symptoms accompanying basal ganglia abnormalities on imaging—features that may help distinguish this post-/para-infectious complication.

Diagnostic / clinical pearl

Consider mumps-associated basal ganglia encephalitis when acute movement or behavioral changes follow parotitis or a febrile illness, particularly when imaging shows basal ganglia abnormalities and mumps serology is positive.

Why it matters

The authors report slower recovery and longer hospitalization than with other mumps complications, underscoring the potential morbidity of this neurologic presentation.

Source

Published in J Child Neurol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.